In a study published last month, the drug showed greater rates of pain and symptom relief from migraine compared to a placebo, with more than 19% of participants given the drug reporting to be pain-free within two hours and nearly 40% relieved of the most bothersome symptoms linked to migraine, which include light and noise sensitivity. This is compared to roughly 12% and 28%, respectively, from the placebo. Nausea, sleepiness and dry mouth were the most commonly reported side effects.
Prior to treatment, patients involved in the studies reported moderate to severe migraine pain, with symptoms such as nausea and sensitivity to light and sound. Results showed that a high percentage of patients were able to gain relief from their migraine pain, some in as little as two hours after treatment. The most common side effect reported was nausea and dry mouth.
For those who suffer from insomnia, the answer is not simple. Of the few medications on the market, many cause a slew of unpleasant and sometimes dangerous side effects. However, recently the FDA approved a new insomnia medication that may serve as an alternative. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep.
"This project will combine the best elements of epigenetic research, bioinformatics, and CRISPR to create a tool that solves a real problem in the field of oncology," Bob Brown, chair of translational oncology in Imperial College's department of surgery and cancer, said in a statement. "The approach of epigenetic editing using CRISPR can potentially target precise epigenetic changes in a personalized manner to specific genes to make tumor cells more sensitive to chemotherapy drugs. Such targeting will avoid some of the non-specific side effects in cancer and normal cells caused by current epigenetic therapies."
Cofactor is a large, structured listing of people, places, and things. Here you can find the description of each topic.